Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it will release financial results and operational highlights for the second quarter of 2026 before hosting a conference call and webcast at 8:30 a.m. ET on Aug. 10, 2026. The company, a fully-integrated commercial-stage biotechnology firm, is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need.
This quarterly report comes on the heels of significant milestones, including the recent FDA approval of TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. Fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties, has long lacked effective therapeutic options. The approval of TONMYA marks a turning point for patients and reinforces Tonix’s commitment to addressing underserved medical conditions.
Tonix’s CNS commercial infrastructure supports its marketed products, including Zembrace® SymTouch® and Tosymra® for acute migraine. Meanwhile, the company is maximizing the science behind TONMYA through Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder. These studies could expand the drug’s indications, potentially benefiting millions of patients suffering from these debilitating conditions.
In addition to its CNS portfolio, Tonix is advancing a pipeline of immunology programs. Among these is TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. Both programs address critical unmet needs: Lyme disease affects hundreds of thousands annually, and transplant rejection remains a major challenge in organ transplantation.
Tonix is also preparing TNX-2900 for Phase 2 trials targeting Prader-Willi syndrome, a rare genetic disorder that causes severe metabolic, behavioral, and intellectual challenges. With no approved treatments for many aspects of the syndrome, TNX-2900 could offer a new therapeutic avenue.
The upcoming earnings call will provide investors and stakeholders with updates on these pipeline developments, financial performance, and operational progress. A replay of the webcast will be available in the Investors section of the company’s website following the event. For more information, visit the company’s newsroom at https://ibn.fm/TNXP.
The full press release is accessible at https://ibn.fm/A9CfR. As Tonix continues to build on its recent successes, the second-quarter report will be a key indicator of the company’s trajectory in both CNS and immunology sectors.
